TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01836835

Intervention type: OTHER
Intervention: Pregnancy Unique Questionnaire of Emesis (PUQE)
Description: For hyperemesis gravidarum patients the Pregnancy Unique Questionnaire of Emesis (PUQE) (3 questions regarding the amount of nausea and vomiting during 24 hours) will be answered both at hospital admittance and discharge. For control patients the questionnaire will be answered at inclusion.

Intervention type: OTHER
Intervention: Pregnancy Unique Questionnaire of Emesis (PUQE)
Description: For hyperemesis gravidarum patients the Pregnancy Unique Questionnaire of Emesis (PUQE) (3 questions regarding the amount of nausea and vomiting during 24 hours) will be answered both at hospital admittance and discharge. For control patients the questionnaire will be answered at inclusion.

Intervention type: OTHER
Intervention: 24 hours self-reported nutritional intake form
Description: A nutritional intake form where relevant food and liquid items can be checked prospectively after consummation during 24 hours. This form will be filled in starting the morning following inclusion.

Intervention type: OTHER
Intervention: 24 hours self-reported nutritional intake form
Description: A nutritional intake form where relevant food and liquid items can be checked prospectively after consummation during 24 hours. This form will be filled in starting the morning following inclusion.
Study: NCT02145975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: The nurse will administer 1 ug per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS \> 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 100 ug of fentanyl which is diluted in 10 mL of normal saline leaving a 10μg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: The nurse will administer 0,1 mg per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS \> 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 10 mg of morphine which is diluted in 10 mL of normal saline leaving a 1 mg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized.
Study: NCT03430375

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alternating air wheelchair cushion
Description: The Ease alternating air cushion has longitudinal air bladders which alternately inflate and deflate at 3 minutes intervals in order to change the areas of pressure to the skin for areas in contact with the wheelchair cushion/seat (buttock and posterior thighs). The Ease Alternating Pressure wheelchair cushion is 510(k) exempt.
Study: NCT01712867

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 acid ethyl esters
Description: 4 capsules/day for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phytosterol esters of omega-3
Description: 4 capsules/day for 12 weeks
Study: NCT01290679

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a or peginterferon alfa-2b and ribavirin for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a or peginterferon alfa-2b and ribavirin for 24 or 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b)
Description: One subcutaneous (under the skin) injection of PegIFNα-2a (containing 0.5 mL solution with 180 mcg PegIFNα-2a) OR PegIFNα-2b (0.5 mL from a pre-filled pen) once weekly for up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b)
Description: One subcutaneous (under the skin) injection of PegIFNα-2a (containing 0.5 mL solution with 180 mcg PegIFNα-2a) OR PegIFNα-2b (0.5 mL from a pre-filled pen) once weekly for up to 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin (RBV)
Description: 200-mg tablets of ribavirin (Copegus or Rebetol) (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: 200-mg tablets of ribavirin (Copegus or Rebetol) (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
Study: NCT03507764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of the treadmill workstation at work
Description: During the randomized study phase, provision of the treadmill workstation with the recommendation to use it for at least one hour (continuous or split) during each of the working shifts.~After six months, all subjects will use treadmill without restrictions or conditions.
Study: NCT00993343

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus/tacrolimus
Description: Standard GVHD prophylaxis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine/methotrexate
Description: Standard GVHD prophylaxis
Study: NCT01720498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: The effect site concentration of remifentanil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: The effect site concentration of remifentanil
Study: NCT03613649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0914
Description: Spiropyrimidinetrione antibacterial drug, which inhibits bacterial DNA synthesis by a novel mechanism. Powder will be reconstituted in 60 mL of tap water and dosed orally after an overnight fast. After the cup containing 60 mL of zoliflodacin is taken, approximately 60 mL of tap water will be added to the cup and consumed by the subject to chase the initial dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0914
Description: Spiropyrimidinetrione antibacterial drug, which inhibits bacterial DNA synthesis by a novel mechanism. Powder will be reconstituted in 60 mL of tap water and dosed orally after an overnight fast. After the cup containing 60 mL of zoliflodacin is taken, approximately 60 mL of tap water will be added to the cup and consumed by the subject to chase the initial dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Broad-spectrum 8-methoxy fluoroquinolone with activity against both Gram-positive and Gram-negative bacteria, including anaerobes. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride will be administered orally with 120 mL of tap water.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Composed of 4 g of the same excipients found in zoliflodacin. Powder will be reconstituted in 60 mL of tap water and dosed orally after an overnight fast. After the cup containing 60 mL of placebo is taken, approximately 60 mL of tap water will be added to the cup and consumed by the subject to chase the initial dose.
Study: NCT03814720

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUNPF099-00-VP (H1ssF_3928)
Description: The vaccine is composed of the HA stem domain from Influenza A/New Caledonia/20/1999 (H1N1) genetically fused to the ferritin protein from H. pylori. Purified H1ssF_3928 particles display eight well-formed HA trimers that antigenically resemble the native H1 stem viral spikes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUNPF099-00-VP (H1ssF_3928)
Description: The vaccine is composed of the HA stem domain from Influenza A/New Caledonia/20/1999 (H1N1) genetically fused to the ferritin protein from H. pylori. Purified H1ssF_3928 particles display eight well-formed HA trimers that antigenically resemble the native H1 stem viral spikes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUNPF099-00-VP (H1ssF_3928)
Description: The vaccine is composed of the HA stem domain from Influenza A/New Caledonia/20/1999 (H1N1) genetically fused to the ferritin protein from H. pylori. Purified H1ssF_3928 particles display eight well-formed HA trimers that antigenically resemble the native H1 stem viral spikes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUNPF099-00-VP (H1ssF_3928)
Description: The vaccine is composed of the HA stem domain from Influenza A/New Caledonia/20/1999 (H1N1) genetically fused to the ferritin protein from H. pylori. Purified H1ssF_3928 particles display eight well-formed HA trimers that antigenically resemble the native H1 stem viral spikes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUNPF099-00-VP (H1ssF_3928)
Description: The vaccine is composed of the HA stem domain from Influenza A/New Caledonia/20/1999 (H1N1) genetically fused to the ferritin protein from H. pylori. Purified H1ssF_3928 particles display eight well-formed HA trimers that antigenically resemble the native H1 stem viral spikes.
Study: NCT04392128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate 200 MG [Plaquenil]
Description: Hydroxychloroquine is an anti-malarial drug also used as anti-inflammatory treatment for systemic lupus erythematosus and rheumatic disorders. HCQ also inhibits pH-dependant replication stages of diverse types of viruses including flavivirus, retrovirus and coronaviruses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin 250 MG Oral Capsule
Description: Azithromycin is amacrolide antibiotic.
Study: NCT04531163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N Acetylcysteine
Description: (NAC) is a drug used in the experiment and participant are treated with it by 1200mg/day dose for two months.
Study: NCT03430375

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Static air cushion
Description: The Roho static air cushion is composed of multiple air bladders that are inflated to proper levels according to the individual's weight. This cushion is commonly used for individuals post spinal cord injury and sometime for individuals post stroke. The Roho wheelchair cushion is 510(k) exempt.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Static air cushion
Description: The Roho static air cushion is composed of multiple air bladders that are inflated to proper levels according to the individual's weight. This cushion is commonly used for individuals post spinal cord injury and sometime for individuals post stroke. The Roho wheelchair cushion is 510(k) exempt.
Study: NCT02470195

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: workshop
Description: workshop for procedural simulation for education in difficult airway situation
Study: NCT00226720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Outpatient detoxification program
Description: Outpatient detoxification program

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient detoxification program
Description: Outpatient detoxification program
Study: NCT03473782

Intervention type: OTHER
Intervention: Voiding Diary
Description: A log kept by each patient to record frequency and volume of urine output and fluid input.
Study: NCT01828593

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serum-derived bovine immunoglobulin protein isolate (SBI)
Description: SBI is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. SBI does not contain any milk products such as lactose, casein, or whey. SBI is gluten-free, dye-free, and soy-free. SBI is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients.
Study: NCT03473782

Intervention type: OTHER
Intervention: Voiding Diary
Description: A log kept by each patient to record frequency and volume of urine output and fluid input.

Intervention type: OTHER
Intervention: Urodynamics Correlation Study
Description: Provides patho physiological data by assessing bladder sensation, bladder capacity, the presence of involuntary bladder contractions, bladder compliance and bladder outlet obstruction.

Intervention type: OTHER
Intervention: Urodynamics Correlation Study
Description: Provides patho physiological data by assessing bladder sensation, bladder capacity, the presence of involuntary bladder contractions, bladder compliance and bladder outlet obstruction.
Study: NCT04392128

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo of Hydroxychloroquine Sulfate 200 MG \[Plaquenil\].

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo of Azithromycin capsules.
Study: NCT03662191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis
Description: bioavailability study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis
Description: bioavailability study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis
Description: bioavailability study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis
Description: bioavailability study
Study: NCT03377270

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respiratory Swallow Training
Description: Training in the Optimal Respiratory Swallow Pattern and Lung Volume at Swallow Initiation
Study: NCT03546036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Weighted metal chain blanket
Description: Use of a weighted metal chain blanket of 8 kg

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control plastic chain blanket
Description: A blanket with light plastic chains
Study: NCT00993187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin/Metformin FDC
Description: Sitagliptin phosphate plus metformin hydrochloride combination tablet (MK-0431A) orally up to 50/1000 mg BID for 30 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Glimepiride
Description: Glimepiride tablet orally up to 6 mg daily for 30 Weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching placebo to Sitagliptin/Metformin FDC
Description: Matching placebo to Sitagliptin/Metformin FDC 50/1000 mg orally BID for 30 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo to glimepiride
Description: Matching placebo to glimepiride tablet orally daily for 30 weeks
Study: NCT05133895

Intervention type: DRUG
Intervention: Tocilizumab monotherapy
Description: intravenous infusions of TCZ (8 mg/kg) at inclusion and then every 4 weeks for at least 3 months
Study: NCT01173809

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Patient will continue taking Amiodarone before, during and after ablation (8 weeks post-ablation).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Amiodarone therapy will be stopped at least 5-months before ablation procedure and ablation will be performed off Amiodarone. Patients will not take Amiodarone during the blanking period (8 weeks post-ablation).
Study: NCT02496026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS plus wrist robot therapy
Description: Patients receive robotic rehabilitation session while tDCS stimulator is switched on

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS plus wrist robot therapy
Description: Patients receive robotic rehabilitation session while tDCS stimulator is switched off.
Study: NCT01828593

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serum-derived bovine immunoglobulin protein isolate (SBI)
Description: SBI is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. SBI does not contain any milk products such as lactose, casein, or whey. SBI is gluten-free, dye-free, and soy-free. SBI is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT01624129

Intervention type: DRUG
Intervention: Fluticasone
Description: Guideline-based treatment with fluticasone 0,5 ml (1-0-1), step-up or step-down after 3 months based on the histopathological findings
Study: NCT03225677

Intervention type: PROCEDURE
Intervention: blood draw and muscle biopsy
Description: One venous catheter will be used for bolus injection of multiple labeled AA at the beginning .The second venous catheter will inserted in the other arm for 5 ml of arterialized venous blood draw.Following the infusions, a single muscle biopsy will be performed from the vastus lateralis of the thigh using the Bergstromm needle.

Intervention type: PROCEDURE
Intervention: blood draw and muscle biopsy
Description: One venous catheter will be used for bolus injection of multiple labeled AA at the beginning .The second venous catheter will inserted in the other arm for 5 ml of arterialized venous blood draw.Following the infusions, a single muscle biopsy will be performed from the vastus lateralis of the thigh using the Bergstromm needle.
Study: NCT03626090

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous BM MSC
Description: A total of 100-200ml will be harvested from the subject, in either a single or multiple punctures. This will be processed for autologous MSC infusion.
Study: NCT02920229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga- PSMA
Description: 100-200 MBq of 68Ga-PSMA will be injected intravenously prior to perform the PET/CT
Study: NCT00865943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram HBr eq. 10 mg tablets, single dose
Description: A: Experimental Subjects received Purepac formulated products under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CELEXATM 10 mg tablets, single dose
Description: B: Active comparator Subjects received Forest Pharmaceuticals, Inc. marketed products under fasting conditions
Study: NCT01768546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Diabetes Prevention Program
Description: Participants will view 16 Video On Demand reality based TV episodes that follow 6 adults with pre-diabetes actively participating in a DPP lifestyle intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Diabetes Prevention Program
Description: Participants will view 16 Video On Demand reality based TV episodes that follow 6 adults with pre-diabetes actively participating in a DPP lifestyle intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive tracking and problem solving web portal
Study: NCT00586170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EBI Bone Healing System
Description: 10 hours of treatment per day for up to 24 weeks

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Device
Description: 10 hours of treatment per day for up to 24 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Open Reduction and Internal Fixation of the nonunion site

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgery
Description: Open Reduction and Internal Fixation of the nonunion site
Study: NCT03755167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPL344
Description: IPL344 will be administered by intravenously (IV) infusion once a day (every 24±6 hours), using a Peripherally Inserted Central Catheter (PICC) line or a permanent port. IPL344 will be administered using an electronic pump at a flow rate that will be determined in protocol 101/2. The dose will be fixed as MTD as established in protocol 101/2 (up to 3.2 mg/kg).
Study: NCT01986101

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM-13496
Description: SM-13496 20mg for Days 1-7 and beginning Day 8 flexibly dosed 20-60 mg/day for Weeks 2-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM-13496
Description: SM-13496 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6, 80 mg/day on Day 7 and beginning Day 8 flexibly dosed 80-120 mg/day for Weeks 2-6
Study: NCT03114917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive AppRoaches to coMbatting Suicidality (CARMS)
Description: The investigators' psychological therapy is a recovery-focused, structured, time-limited, socio-cognitive intervention. It is based upon the investigators' recently developed treatment manual (Tarrier et al., 2013) and pilot RCTs in the community (Tarrier et al., 2014) and in prison (Tarrier et al., accepted). The intervention modifies negative appraisals of emotional regulation, social support, and interpersonal problem-solving. As a consequence, perceptions of defeat, entrapment, and hopelessness will be improved indirectly. In addition, perceptions of defeat, entrapment, and hopelessness will be worked on directly during the therapy.
Study: NCT04045093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: Subjects will be randomized into 2 groups in a 1:1 ratio, to receive either Dabigatran or Warfarin for stroke prevention, in a open-label design.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Subjects will be randomized into 2 groups in a 1:1 ratio, to receive either Dabigatran or Warfarin for stroke prevention, in a open-label design.
Study: NCT02628132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be given weekly for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be given q2 wks concurrently with paclitaxel.
Study: NCT00576732

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution qd or bid for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone high dose
Description: Risperidone oral solution 1.25 mg (if \<45 kg) or 1.75 mg (if \>=45 kg) qd or bid for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone low dose
Description: Risperidone oral solution 0.125 mg (if \<45 kg) or 0.175 mg (if \>=45 kg) qd or bid for 6 weeks
Study: NCT01339286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atomoxetine
Description: Atomoxetine will be titrated to optimal dose, beginning with 0.5mg/kg.d, then increasing to 1.2mg/kg.d in two weeks and maintaining for 4 weeks. If the optimal dose does not achieved, the dose can be increased further to 1.4mg/kg.d and maintained for 4 weeks.